Evolent Health (EVH) Tops Q1 EPS by 6c

Evolent Health (NYSE: EVH) reported Q1 EPS of $0.02, $0.06 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $144.4 million versus the consensus estimate of $140.6 million.

Business Outlook

For the full year 2018, Adjusted Revenue is expected to be in the range of approximately $565.0 million to $585.0 million. The components of Adjusted Revenue include Adjusted Services Revenue, which is forecasted to be approximately $495.0 million to $510.0 million, and True Health premiums revenue, which is forecasted to be approximately $90.0 million to $95.0 million; Intersegment eliminations are forecasted to be approximately $(20.0) million for the full year. Adjusted EBITDA is expected to be in the range of approximately $18.0 million to $23.0 million.

For the three months ended June 30, 2018, Adjusted Revenue is expected to be in the range of approximately $139.0 million to $143.0 million. The components of Adjusted Revenue include Adjusted Services Revenue, which is forecasted to be approximately $122.0 million to $124.0 million, and True Health premiums revenue, which is forecasted to be approximately $22.0 million to $24.0 million; Intersegment eliminations are forecasted to be approximately $(5.0) million for the quarter. Adjusted EBITDA is expected to be in the range of approximately $3.0 million to $5.0 million.

For earnings history and earnings-related data on Evolent Health (EVH) click here.

You May Also Be Interested In

• Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
• Centene (CNC) Tops Q1 EPS by 18c; Raises guidance
• Chevron (CVX) Misses Q1 EPS by 3c